BIOMARIN PHARMACEUTICAL INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 45.00% for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-08-02.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2012-08-02
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2012-06-30 was 45.00%, a 6.25% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2012-03-31 was 46.00%, a 8.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2011-06-30 was 48.00%.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2011-03-31 was 50.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month |
|---|---|---|
| 2012-06-30 | 45.00% 10-Q · filed 2012-08-02 | 45.00% 10-Q · filed 2012-08-02 |
| 2012-03-31 | 46.00% 10-Q · filed 2012-04-30 | |
| 2011-06-30 | 48.00% 10-Q · filed 2012-08-02 | 48.00% 10-Q · filed 2012-08-02 |
| 2011-03-31 | 50.00% 10-Q · filed 2012-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |